ArticleCureus2025
Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in a 56-Year-Old Filipino Female With Relapsing and Remitting Multiple Sclerosis: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is the most common autoimmune demyelinating disease of the central nervous system. Treatment options include oral, subcutaneous, and intravenous disease-modifying therapies (DMT). An alternative therapy in the treatment of MS is autologous hematopoietic stem cell transplantation (aHSCT). It has been shown to benefit patients with relapsing and remitting multiple sclerosis (RRMS) who have an inadequate response to DMTs. In this case report, we present the first local documentation of a 56-year-old Filipino female diagnosed with RRMS who underwent aHSCT. Prior to treatment, she was maintained on rituximab for two years and had an expanded disability status scale (EDSS) score of one. Due to the development of new-onset first-degree atrioventricular (AV) block, she was subsequently switched to aHSCT and underwent the procedure without any complications. Two years after treatment, she has not had any relapses, is not on any DMT, has a stable EDSS score of one, and is independent in all her activities of daily living. Our case underscores the utility of considering aHSCT as a possible cost-effective, safe, and effective treatment option for Filipino patients with RRMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.